Additional Development Activities. Except for the 611 Study, 612 Study and BCG Refractory Study, nothing in this Agreement shall prevent Allergan from developing and performing any clinical trials with respect to the Licensed Product in the Field of Use in the Allergan Territory unilaterally and at its own expense. If Allergan requests that Spectrum assist in such trials, and Spectrum agrees to do so and agrees to assist in funding such trials, the Parties shall amend the JDP to govern such trials and the Development Costs incurred in such clinical trials shall be paid as set forth in Section 6.6. Spectrum shall not conduct any development activities with respect to the Licensed Product in the Allergan Territory other than pursuant to this Article 3 or as permitted in Section 2.5(b).
Appears in 2 contracts
Sources: License, Development, Supply and Distribution Agreement (Spectrum Pharmaceuticals Inc), License, Development, Supply and Distribution Agreement (Allergan Inc)